New Treatments for Rare Mutations in NSCLC
Category
  • Oncology
Format
  • Self-study / Enduring
Credits
  • AMA PRA Category 1 Credit™
Applying ADAURA in Practice: Implications for Early Stage EGFRm NSCLC - Medical Moment Two
Medical Moment Two: Expert Insight on Applying the ADAURA Results to Treatment of Early-Stage NSCLC Patients 
Category
  • Oncology
Format
  • Self-study / Enduring
Credits
  • AMA PRA Category 1 Credit™
  • Participation
Applying ADAURA in Practice: Implications for Early Stage EGFRm NSCLC - Medical Moment One
Medical Moment One: Expert Insight on Practical Aspects of Molecular Profiling for Early-Stage NSCLC Cancers 
Category
  • Oncology
Format
  • Self-study / Enduring
Credits
  • AMA PRA Category 1 Credit™
  • Participation
How Do We Identify HER2+ Gastric Cancer?
The implementation of molecular testing, especially analysis of human epidermal growth factor receptor 2 (HER2) status, has had a significant impact on clinical practice and patient care. Join Drs.
Category
  • Oncology
Format
  • Self-study / Enduring
Credits
  • AMA PRA Category 1 Credit™
  • Participation
How Do Antibody-Drug Conjugates (ADCs) Fit into Precision Medicine for Gastric Cancer?
Antibody-drug conjugates or “ADCs” are a novel class of highly potent biopharmaceutical drug composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound. Nearly 150 investigational ADCs are currently in pre-clinical and clinical trials. Join Drs.
Category
  • Oncology
Format
  • Self-study / Enduring
Credits
  • AMA PRA Category 1 Credit™
  • Participation
What’s the Best Approach to Select Targeted Treatments for HER2+ Gastric Cancer and What are Practical Considerations?
Clinicians must be aware and up-to-date on the most effective approaches to management in order to provide patients with the most appropriate course of therapy. Join Drs.
Category
  • Oncology
Format
  • Self-study / Enduring
Credits
  • AMA PRA Category 1 Credit™
  • Participation
2020 and Beyond: How Immunotherapy is Changing the Game in Bladder Cancer Management
It is estimated that there are >81,000 new cases of metastatic urothelial bladder cancer (mUBC) in the U.S each year, resulting in more than 17,000 bladder cancer specific deaths.
Category
  • Oncology
Format
  • Webinar recorded
Credits
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
Focusing on the Role of the Advanced Bladder Cancer Care Team: Case Studies on Managing irAEs
Join Drs. Neal Shore, Gautam Jayram, and Nurse Tanya O’Neal as they discuss clinical considerations for managing immune-related adverse events that may occur at any time during therapy and, as of yet, there is no reliable means to predict who will develop them.
Category
  • Oncology
Format
  • Webinar recorded
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
IO Therapies in the Advanced Bladder Cancer Clinic: Aligning Your Team for Success
As the treatment paradigm for bladder cancer continuously evolves, all members of the oncology healthcare team must be equipped to evolve with it to ensure optimal patient care. With this evolution comes many questions for the bladder cancer treatment team. Join Drs.
Category
  • Oncology
Format
  • Webinar recorded
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
Future Directions in Bladder Cancer Treatment: The Experts Weigh In
Immunotherapies are revolutionizing many cancer treatment regimens and show promise in locally advanced or metastatic bladder cancer. Immune checkpoint inhibitors are attempting to fill an unmet need in relapsed disease and biomarkers may assist in identifying patients most likely to respond.
Category
  • Oncology
Format
  • Webinar recorded
Credits
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation

Pages